Atopic Dermatitis

Dupilumab provides option for severe AD in younger children
October 21, 2020

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.

Older adults underrepresented in atopic dermatitis research
October 20, 2020

A recent review reveals older adults are underrepresented in trials investigating systemic immunomodulators as a treatment for atopic dermatitis.

Dupilumab outlasts cyclosporine
September 21, 2020

Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.

Lebrikizumab rapidly improves quality of life
September 16, 2020

Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.

Tralokinumab demonstrates long-term success in phase 3
August 25, 2020

In clinical trials, most patients treated with tralokinumab maintained 75% reductions in EASI scores for one year.

Drug vehicles deliver benefits
August 25, 2020

Vehicles for topical atopic dermatitis treatments deliver benefits that promote barrier restoration and enhance innate immune defenses, a review suggests.

Tape strips detect eczema, psoriasis biomarkers
August 18, 2020

Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.

FDA grants delgocitinib fast track designation for chronic hand eczema
August 05, 2020

The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.

Experts discuss pediatric atopic dermatitis treatments
July 24, 2020

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

FDA accepts BLA for tralokinumab for atopic dermatitis
July 09, 2020

The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.